Core Viewpoint - Agilent Technologies, Inc. is a leading provider of solutions in life sciences, diagnostics, and applied chemical markets, with a market cap of $39.6 billion and is expected to announce its fiscal first-quarter earnings for 2026 soon [1] Financial Performance - Analysts anticipate Agilent to report a profit of $1.37 per share on a diluted basis for the upcoming quarter, reflecting a 4.6% increase from $1.31 per share in the same quarter last year [2] - For the full fiscal year, the expected EPS is $5.93, which is a 6.1% increase from $5.59 in fiscal 2025, and projected to rise to $6.54 in fiscal 2027, marking a 10.3% year-over-year growth [3] Stock Performance - Agilent's stock has underperformed the S&P 500 Index, which gained 13.3% over the past 52 weeks, with Agilent shares down 7.8% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund, which saw a 10.9% increase in the same timeframe [4] Recent Earnings Report - On November 25, 2025, Agilent shares rose over 2% after reporting Q4 results, with an adjusted EPS of $1.59 meeting Wall Street expectations and revenue of $1.9 billion exceeding forecasts of $1.8 billion [5] - The company expects full-year adjusted EPS to be between $5.86 and $6, with revenue projected between $7.3 billion and $7.4 billion [5] Analyst Ratings - The consensus opinion on Agilent stock is moderately bullish, with a "Moderate Buy" rating overall; out of 18 analysts, 12 recommend a "Strong Buy," one a "Moderate Buy," and five a "Hold" [6] - The average analyst price target for Agilent is $170.67, indicating a potential upside of 25.6% from current levels [6]